How to buy Abiomed stock | $281.47

Abiomed, Inc is a medical devices business based in the US. Abiomed shares (ABMD) are listed on the NASDAQ and all prices are listed in US Dollars. Abiomed employs 1,536 staff and has a trailing 12-month revenue of around USD$802.9 million.

How to buy shares in Abiomed

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Abiomed. Find the stock by name or ticker symbol: ABMD. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Abiomed reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$281.47, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Abiomed, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Abiomed. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Abiomed share price

Use our graph to track the performance of ABMD stocks over time.

Abiomed shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$281.47
52-week range	USD$119.0101 - USD$319.19
50-day moving average	USD$274.4488
200-day moving average	USD$277.4002
Wall St. target price	USD$324.6
PE ratio	66.6835
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$4.55

Buy Abiomed shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Abiomed stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Abiomed, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Abiomed price performance over time

Historical closes compared with the close of $281.47 from 2020-10-19

1 week (2021-01-11)	-13.28%
1 month (2020-12-18)	-4.06%
3 months (2020-10-16)	-1.75%
6 months (2020-07-17)	-1.08%

1 year (2020-01-17)	55.27%
2 years (2019-01-18)	-15.66%
3 years (2018-01-18)	24.60%
5 years (2016-01-15)	222.01%

Is Abiomed under- or over-valued?

Valuing Abiomed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abiomed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Abiomed's P/E ratio

Abiomed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 67x. In other words, Abiomed shares trade at around 67x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Abiomed's PEG ratio

Abiomed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abiomed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Abiomed's EBITDA

Abiomed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$248 million.

The EBITDA is a measure of a Abiomed's overall financial performance and is widely used to measure a its profitability.

Abiomed financials

Revenue TTM	USD$802.9 million
Operating margin TTM	28.09%
Gross profit TTM	USD$689.6 million
Return on assets TTM	11.49%
Return on equity TTM	19.12%
Profit margin	25.88%
Book value	$26.165
Market capitalisation	USD$13.7 billion

TTM: trailing 12 months

Shorting Abiomed shares

There are currently 1.9 million Abiomed shares held short by investors – that's known as Abiomed's "short interest". This figure is 5.6% down from 2.1 million last month.

There are a few different ways that this level of interest in shorting Abiomed shares can be evaluated.

Abiomed's "short interest ratio" (SIR)

Abiomed's "short interest ratio" (SIR) is the quantity of Abiomed shares currently shorted divided by the average quantity of Abiomed shares traded daily (recently around 223256.8627451). Abiomed's SIR currently stands at 8.67. In other words for every 100,000 Abiomed shares traded daily on the market, roughly 8670 shares are currently held short.

However Abiomed's short interest can also be evaluated against the total number of Abiomed shares, or, against the total number of tradable Abiomed shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abiomed's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Abiomed shares in existence, roughly 40 shares are currently held short) or 0.049% of the tradable shares (for every 100,000 tradable Abiomed shares, roughly 49 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Abiomed.

Find out more about how you can short Abiomed stock.

Abiomed share dividends

We're not expecting Abiomed to pay a dividend over the next 12 months.

Have Abiomed's shares ever split?

Abiomed's shares were split on a 2:1 basis on 2 October 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Abiomed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Abiomed shares which in turn could have impacted Abiomed's share price.

Abiomed share price volatility

Over the last 12 months, Abiomed's shares have ranged in value from as little as $119.0101 up to $319.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abiomed's is 1.358. This would suggest that Abiomed's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Abiomed overview

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Frequently asked questions

• What percentage of Abiomed is owned by insiders or institutions?

  Currently 2.344% of Abiomed shares are held by insiders and 98.103% by institutions.

• How many people work for Abiomed?

  Latest data suggests 1,536 work at Abiomed.

• When does the fiscal year end for Abiomed?

  Abiomed's fiscal year ends in March.

• Where is Abiomed based?

  Abiomed's address is: 22 Cherry Hill Drive, Danvers, MA, United States, 01923

• What is Abiomed's ISIN number?

  Abiomed's international securities identification number is: US0036541003

• What is Abiomed's CUSIP number?

  Abiomed's Committee on Uniform Securities Identification Procedures number is: 003654100